Healthcare makes up a full 20 percent of the American economy.
Accordingly, small changes in regulations or technology create massive opportunities.
Today, billions of healthcare spending is moving to a handful of new companies because of a single new technology: Genetic Diagnostics.
In the past 24 months, the cost of genetic testing has dropped dramatically, and the diagnostic business is booming.
Nearly all the traditional drug and healthcare companies are unprepared for this transition, and will see their businesses disrupted.
Why? Well, genetic diagnostics – when done right – offers a revolutionary value proposition.
Genomic information can indicate your susceptibility to diseases including cancer, diabetes, and cystic fibrosis.
And not only can genetic tests predict disease, they can also predict the effectiveness of common drug treatments, including pain and diabetes medications, and treatments for obesity and hypertension.
Quite simply, doctors, clinics, hospitals, patients, and diagnostic labs need genetic tests to make major healthcare decisions for patients.
And the companies – many of them still in their startup and early, emerging growth phases - that create, distribute, and conduct these tests are having rocket ship growth.